BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 37014535)

  • 1. Immune checkpoint inhibitor-associated acute kidney injury in patients with cancer: a systematic review and meta-analysis of risk factors.
    Yan H; Tang M; Zhu W; Yang Y
    Clin Exp Nephrol; 2023 Jul; 27(7):603-612. PubMed ID: 37014535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence and risk factors of acute kidney injury in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
    Liu C; Wei W; Yang L; Li J; Yi C; Pu Y; Yin T; Na F; Zhang L; Fu P; Zhao Y
    Front Immunol; 2023; 14():1173952. PubMed ID: 37313406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors of immune checkpoint inhibitor-associated acute kidney injury: evidence from clinical studies and FDA pharmacovigilance database.
    Chen P; Zhu J; Xu Y; Huang Q; Su J; Gao Z; Feng M
    BMC Nephrol; 2023 Apr; 24(1):107. PubMed ID: 37087434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?
    Franzin R; Netti GS; Spadaccino F; Porta C; Gesualdo L; Stallone G; Castellano G; Ranieri E
    Front Immunol; 2020; 11():574271. PubMed ID: 33162990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute kidney injury associated with immune checkpoint inhibitors: A pharmacovigilance study.
    Zhu J; Wu J; Chen P; You K; Su J; Gao Z; Bi Z; Feng M
    Int Immunopharmacol; 2022 Dec; 113(Pt A):109350. PubMed ID: 36272360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Renal Toxicity: Illustrative Case and Review.
    Sise ME; Seethapathy H; Reynolds KL
    Oncologist; 2019 Jun; 24(6):735-742. PubMed ID: 30902916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors for adverse events induced by immune checkpoint inhibitors in patients with non-small-cell lung cancer: a systematic review and meta-analysis.
    Suazo-Zepeda E; Bokern M; Vinke PC; Hiltermann TJN; de Bock GH; Sidorenkov G
    Cancer Immunol Immunother; 2021 Nov; 70(11):3069-3080. PubMed ID: 34195862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients.
    Song P; Zhang D; Cui X; Zhang L
    Thorac Cancer; 2020 Sep; 11(9):2406-2430. PubMed ID: 32643323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence, predictors, and survival impact of acute kidney injury in patients with melanoma treated with immune checkpoint inhibitors: a 10-year single-institution analysis.
    Abdelrahim M; Mamlouk O; Lin H; Lin J; Page V; Abdel-Wahab N; Swan J; Selamet U; Yee C; Diab A; Suki W; Abudayyeh A
    Oncoimmunology; 2021 May; 10(1):1927313. PubMed ID: 34104543
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparative risk of acute kidney injury among cancer patients treated with immune checkpoint inhibitors.
    Liu F; Wang Z; Li X; Zhang Z; Yang Y; Chen J; Chen D; Wu L; Liu X; Han S; Wang F; Wahafu W; Gao Y; Ren S; Xing N; Cai G; Chen X
    Cancer Commun (Lond); 2023 Feb; 43(2):214-224. PubMed ID: 36528491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence, mortality, and risk factors of acute kidney injury after immune checkpoint inhibitors: Systematic review and meta-analysis of real-world evidence.
    Xie W; Xiao S; Li X; Huang J; Li G; Zhang Z
    Eur J Intern Med; 2023 Sep; 115():88-95. PubMed ID: 37263805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal adverse effects of immune checkpoints inhibitors in clinical practice: ImmuNoTox study.
    Espi M; Teuma C; Novel-Catin E; Maillet D; Souquet PJ; Dalle S; Koppe L; Fouque D
    Eur J Cancer; 2021 Apr; 147():29-39. PubMed ID: 33607383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence, predictors and 6-month overall outcome of acute kidney injury in Chinese patients receiving PD-1 inhibitors.
    Qin Z; Liu K; Xu X; Li T; Ge Y; Wu B; Xing C; Mao H
    Future Oncol; 2022 May; 18(16):1951-1962. PubMed ID: 35232231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors for immune-mediated hepatotoxicity in patients with cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
    Pan J; Liu Y; Guo X; Bai Z; Levi Sandri GB; Méndez-Sánchez N; Qi X
    Expert Opin Drug Saf; 2022 Oct; 21(10):1275-1287. PubMed ID: 36214583
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence, risk factors and prognosis of acute kidney injury in patients treated with immune checkpoint inhibitors: a retrospective study.
    Ji MS; Wu R; Feng Z; Wang YD; Wang Y; Zhang L; Sun XF; Chen XM; He KL; Cai GY
    Sci Rep; 2022 Nov; 12(1):18752. PubMed ID: 36335144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes.
    Meraz-Muñoz A; Amir E; Ng P; Avila-Casado C; Ragobar C; Chan C; Kim J; Wald R; Kitchlu A
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32601079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute Kidney Injury Induced by Immune Checkpoint Inhibitors in Lung Cancer Patients.
    Lv D; He L; Guo L; Zhang X; He X
    Discov Med; 2022; 33(170):137-141. PubMed ID: 36274242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors associated with immune checkpoint inhibitor-induced acute kidney injury compared with other immune-related adverse events: a case-control study.
    Gérard AO; Barbosa S; Parassol N; Andreani M; Merino D; Cremoni M; Laurain A; Pinel S; Bourneau-Martin D; Rocher F; Esnault VLM; Borchiellini D; Sicard A; Drici MD;
    Clin Kidney J; 2022 Oct; 15(10):1881-1887. PubMed ID: 36158153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute kidney injury in patients treated with immune checkpoint inhibitors.
    Gupta S; Short SAP; Sise ME; Prosek JM; Madhavan SM; Soler MJ; Ostermann M; Herrmann SM; Abudayyeh A; Anand S; Glezerman I; Motwani SS; Murakami N; Wanchoo R; Ortiz-Melo DI; Rashidi A; Sprangers B; Aggarwal V; Malik AB; Loew S; Carlos CA; Chang WT; Beckerman P; Mithani Z; Shah CV; Renaghan AD; Seigneux S; Campedel L; Kitchlu A; Shin DS; Rangarajan S; Deshpande P; Coppock G; Eijgelsheim M; Seethapathy H; Lee MD; Strohbehn IA; Owen DH; Husain M; Garcia-Carro C; Bermejo S; Lumlertgul N; Seylanova N; Flanders L; Isik B; Mamlouk O; Lin JS; Garcia P; Kaghazchi A; Khanin Y; Kansal SK; Wauters E; Chandra S; Schmidt-Ott KM; Hsu RK; Tio MC; Sarvode Mothi S; Singh H; Schrag D; Jhaveri KD; Reynolds KL; Cortazar FB; Leaf DE;
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34625513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy with immune check point inhibitors and acute kidney injury.
    Valentin A; Møller AKH; Palshof JA; Broberg B; Gravesen E; Svane IM; Hansen D
    Acta Oncol; 2023 Feb; 62(2):121-125. PubMed ID: 36755491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.